PARKINSON KASALLIGIDA MOTOR FLUKTUATSIYАLARNI BEMORLAR PSIXOEMOTSIONAL HOLATI VA YАSHASH SIFATIGA TA’SIRI
Abstrakt
Mavzuning dolzarbligi. Parkinson kasalligi asab tizimining neyrodegnerativ kasalligi hisoblanib, nevrologiyaning eng dolzarb muammolaridan biridir. Motor fluktuatsiyalar Parkinson kasalligi bilan og‘rigan bemorlarda levodopa bilan uzoq muddatli davolashning xos asoratlaridan biri hisoblanadi. Tadqiqot maqsadi. Parkinson kasalligida motor fyuktuatsiyalarni bemorlar psixoemotsional holati va yashash sifatiga ta’sirini o‘rganish. Tadqiqot materiali va usullari. Parkinson kasalligining turli klinik shakllari bilan og‘rib kelayotgan 120 nafar bemorlar ro‘yhatga olindi. Tadqiqot davomida ko‘rsatkichlarini solishtirish maqsadida bemorlar 2 ta guruhga ajratildi, motor flyuktatsiyali bemorlar (55 nafar) va motor fluktuatsiyasiz bemorlar (65 nafar). Barcha bemorlarga klinik-nevrologik tekshiruv va neyropsixologik tadqiqot usullari o‘tkazildi. Tadqiqot natijalari. Motor fluktuatsiyalari mavjud guruhda affektiv buzilishlarning komorbid shakli - ya’ni depressiya + havotir holati sezilarli darajada yuqori uchradi: fluktuatsiyalari bor guruhda - 54,5% (30/55 bemor), fluktuatsiyalari yo‘q guruhda - 24,6% (16/65 bemor). Bu farqning ahamiyatliligi χ² test yordamida baholanganda, p<0,01 ko‘rsatkichi olindi. Demak, motor fluktuatsiyalar psixik buzilishlarning og‘irroq va komorbid (depressiya + xavotir) shakllari bilan kuchli bog‘liq ekanligi ta’kidlanishi mumkin. PDQ-39 shkalasi domenlari asosida olingan natijalardan ko‘rinib turibdiki, psixoemotsional buzilishlar turli darajada hayot faoliyatining deyarli barcha sohalariga salbiy ta’sir ko‘rsatadi. Xulosa. PDQ-39 orqali hayot sifatini baholashda xavotir va depressiya bilan kechuvchi bemorlarda harakatlanish, har kunlik faoliyat, hissiy holat, kognitiv funksiyalar va ijtimoiy qo‘llab-quvvatlash sohalarida ishonchli pasayish kuzatildi. Eng yuqori salbiy ta’sir depressiya va xavotir birgalikda kechgan guruhda qayd etildi.
Nashr sanasi
Mualliflar haqida
Adabiyotlar ro'yxati
Akhmadeeva G.N., Tayupova G.N., Baytimerov A.R., Magzhanov R.V., Khidiyatova I.M., Khusnutdinova E.K. Study of possible risk factors for the development of anxiety-depressive disorders in patients with Parkinson's disease in the Republic of Bashkortostan. Kazan Neurological Bulletin named after A.N. Bekhterev. 2015; 1: 27-31.
Akhmadeeva G.N., Magzhanov R.V. Anxiety-depressive disorders in patients with Parkinson's disease in the Republic of Bashkortostan. Ural Medical Journal. 2015; 2: 44-48
Illarioshkin, S.N. (2015). Current Concepts on the Etiology of Parkinson's Disease // Neurological Journal. 2015. No. 4. pp. 4-13.
Levin O.S., Koloman I.I., Kulikov A.G. "Features of Thermoregulation in Patients with Parkinson's Disease". S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122(11-2): 19-23.
Timofeeva, A.A. (2016). Invasive Methods in the Treatment of Advanced Stages of Parkinson's Disease: Apomorphine, LCIG, and DBS - a Data Review. S.S. Korsakov Journal of Neurology and Psychiatry, 116(12), 54-60.
Khalimova H.M., Rashidova N.S., Aripov A.N., Matmurodov R.Zh. The role and importance of S100B oxil in the early detection of extrapyramidal diseases// Scientific and practical journal Neurology, Tashkent, 2015.-№4 (64).-P.11-14.
Aquino C. C., Fox S. H. Clinical spectrum of levodopa-induced complications // Mov. Disord. 2015. Vol. 30. N 1. P. 80–89.
Assogna FF, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, Imperiale F, Caltagirone C, Pontieri FE, Spalletta G. Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. Neuropsychiatr Dis Treat. 2013;9:389-396.
Ballanger, B., Strafella, A. P., & Carbon, M. Pimavanserin: Novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy, 2024; 25(8), 1012-1022.
Dissanayaka W., Nadeeka N. Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson’s disease. Parkinsonism & Related Disorders, 36 (2017), 63-68.
Lopez, L., Fox, S. H. Motor- and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis. Frontiers in Neurology, 2022; 13, 919778.
Martinez-Martin, P., Rodríguez-Blázquez, C., Forjaz, M. J., et al. Motor fluctuations development is associated with non-motor symptoms burden progression in Parkinson’s disease patients: A 2-year follow-up study. Journal of Neurology, 2022; 269(4), 1685-1695.
Meltzer, H. Y., & Stahl, S. M. Pimavanserin in the treatment of Parkinson’s disease psychosis: Meta-analysis and meta-regression of randomized clinical trials. CNS Drugs, 2019; 33(6), 591-602.
Skogar O, Nilsson M. Distribution of non-motor symptoms in idiopathic Parkinson’s disease and secondary parkinsonism. J Multidiscip Healthc 2018;11. – P. 525–534.
Subramanian, I., & Sethi, K. D. (2023). Motor fluctuations in Parkinson disease – a mini-review of emerging drugs. Journal of Parkinson’s Disease, 2023, 13(1), 15-29.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.